Anemia :: Researchers urge caution in using ESAs for cancer-related anemia
Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called “erythropoiesis-stimulating agents” (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of the Oncologist, published by AlphaMed Press.